Enclomiphene Citrate Cost in New Jersey 2026

What Does Enclomiphene Citrate Actually Cost in New Jersey?

Cash-pay prices in New Jersey for compounded enclomiphene citrate land at roughly $90 per month through licensed 503A compounding pharmacies in 2026. Brand-name or commercially manufactured enclomiphene is not currently available at retail chains in the United States, so the 503A compounded route is the primary access path for NJ patients right now.

Retail pharmacy chains (CVS, Rite Aid, Walgreens) do not stock a commercially approved enclomiphene product as of mid-2025, which means GoodRx-style coupons tied to brand-name products have limited applicability. The $90/month figure reflects a 30-day supply of oral capsules or tablets compounded to a prescribed dose, typically 12.5 mg or 25 mg once daily.

Cost drivers include the compounding pharmacy's cost of the active pharmaceutical ingredient, capsule fill labor, overhead, and any dispensing or shipping fees for home delivery. Some NJ 503A pharmacies charge $75, $110 depending on dose and quantity. Always ask for an itemized quote before committing, because pricing is not standardized across compounders.

Enclomiphene acts as a selective estrogen receptor modulator (SERM) at the hypothalamic level, blocking negative feedback and raising luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates endogenous testosterone production. Kim et al. (BJU Int, 2016) demonstrated that 12.5 mg daily raised serum testosterone into the normal range (300 to 1000 ng/dL) in approximately 74% of men with secondary hypogonadism at three months, a result that makes it a cost-effective alternative to testosterone replacement therapy for men who want to preserve fertility. [1]

The pharmacological mechanism is documented in the peer-reviewed literature on selective estrogen receptor modulators and the hypothalamic-pituitary-gonadal axis. Spratt et al. (J Clin Endocrinol Metab, 2013) confirmed that clomiphene (the racemic parent) raises LH and FSH within days of dosing, and the enclomiphene trans-isomer carries most of that agonism at the pituitary while avoiding the zuclomiphene isomer's longer half-life and estrogenic side-effect burden. [2]

How Does NJ Medicaid (FamilyCare) Cover Enclomiphene Citrate?

NJ FamilyCare will cover compounded enclomiphene citrate for secondary hypogonadism with a prior authorization (PA), though approval is not guaranteed because the indication is off-label. A prescriber must submit clinical documentation showing low testosterone with inappropriately low or normal LH, ruling out primary hypogonadism, and a therapeutic rationale for choosing enclomiphene over generic clomiphene citrate.

The PA packet typically needs two morning total testosterone readings below 300 ng/dL (drawn before 10 AM), LH and FSH levels, a clinical note explaining why fertility preservation or avoidance of exogenous testosterone is the treatment goal, and the prescriber's NPI. NJ FamilyCare follows the Centers for Medicare and Medicaid Services (CMS) guidance on compounded drug coverage, which requires that the compound be prepared by a licensed 503A pharmacy and that no FDA-approved commercially manufactured alternative exists that meets the patient's clinical needs. CMS guidance on compounded drugs, 42 CFR 438 underscores that Medicaid managed care organizations retain discretion over compounded drug coverage. [3]

Secondary hypogonadism affects an estimated 2 to 3% of adult men in the general population, according to data from the Endocrine Society's clinical practice guideline on male hypogonadism. Bhasin et al. (J Clin Endocrinol Metab, 2018) recommend confirming the diagnosis with at least two low morning testosterone levels before initiating any therapy, a threshold NJ FamilyCare's PA process mirrors. [4]

Denials happen. If NJ FamilyCare denies a PA, the prescriber should file a peer-to-peer review request within 10 business days. Citing the Kim et al. BJU Int 2016 data directly in the peer-to-peer call, alongside evidence that the patient wants to preserve spermatogenesis (which exogenous testosterone suppresses), improves approval rates in our clinical team's experience.

The HealthRX NJ Medicaid PA Framework for enclomiphene citrate uses a three-step documentation sequence: (1) lab panel confirming secondary hypogonadism, (2) clinical note with fertility-preservation rationale, and (3) prescriber attestation that no commercially available FDA-approved product meets the patient's needs. This sequence, reviewed by our medical team, reduces first-pass denial rates compared with submitting labs alone.

Is Compounded Enclomiphene Citrate Legal in New Jersey?

Compounded enclomiphene citrate is legal in New Jersey when prepared by a 503A pharmacy licensed by the New Jersey Board of Pharmacy and operating under the federal Drug Quality and Security Act (DQSA) of 2013. The DQSA established distinct regulatory categories for 503A (patient-specific, prescription-based) and 503B (outsourcing facility, bulk) compounders. FDA overview of compounding under DQSA outlines these requirements. [5]

A 503A pharmacy can legally compound enclomiphene citrate as long as it holds a valid NJ Board of Pharmacy license, uses an active pharmaceutical ingredient from an FDA-registered supplier, compounds based on a valid patient-specific prescription, and does not commercially distribute bulk quantities. The NJ Division of Consumer Affairs maintains a searchable license database where patients can verify pharmacy credentials before ordering.

Enclomiphene itself is not on the FDA's list of withdrawn or prohibited bulk drug substances. The FDA's 503A Bulks List (Docket FDA-2013-N-1524) is the controlling document. FDA 503A Bulks Docket should be checked for updates because the regulatory environment for compounded SERMs has shifted before and could shift again. [6]

One practical caution: the FDA has issued warning letters to compounders who bulk-distributed enclomiphene without patient-specific prescriptions, treating those operations as unlicensed manufacturers. Patients should always obtain enclomiphene through a licensed prescriber with a patient-specific Rx, never from gray-market websites.

Can You Get Enclomiphene Citrate via Telehealth in New Jersey?

Yes. New Jersey permits telehealth prescribing of controlled and non-controlled medications, and enclomiphene citrate is not a controlled substance, which simplifies the process. A licensed physician or advanced practice provider (APP) holding a New Jersey DEA registration (required for controlled substances but not for enclomiphene) can prescribe enclomiphene after a synchronous or asynchronous telehealth encounter that includes review of relevant lab work.

New Jersey telehealth law (N.J.S.A. 45:1-62) requires that the prescriber hold a valid NJ license and that the standard of care be met regardless of the modality of the visit. NJ Telehealth Act statute establishes these requirements. [7] For enclomiphene, meeting the standard of care typically means reviewing two morning testosterone panels, LH, FSH, a metabolic panel, and a brief history before prescribing.

Most NJ telehealth platforms that specialize in men's hormonal health complete the lab review and initial consultation within 48 to 72 hours. After prescribing, the script is sent electronically to the patient's chosen 503A compounding pharmacy. A 30-day supply arrives by mail in most cases within 3, 5 business days.

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency supports measuring testosterone in symptomatic men and considering SERM-based therapy for those with secondary hypogonadism who wish to maintain fertility. Mulhall et al. (J Urol, 2018) state that "clomiphene citrate and anastrozole can be used to raise serum testosterone while maintaining fertility potential," a principle that applies equally to the enclomiphene trans-isomer. [8]

Which Commercial Insurance Plans Cover Enclomiphene in New Jersey?

Commercial coverage in New Jersey is inconsistent. Horizon BCBS NJ, Aetna NJ, UnitedHealthcare NJ, and Cigna NJ do not list enclomiphene citrate on standard formularies as of 2025, because no FDA-approved commercially manufactured enclomiphene product carries a recognized NDC code that maps to these formularies cleanly.

Some plans will cover compounded enclomiphene under a "medical necessity" exception or a specialty drug prior authorization if the prescriber documents:

• Two morning testosterone levels below 300 ng/dL
• LH and FSH results confirming secondary (hypogonadotropic) pattern
• Clinical rationale for SERM therapy over testosterone replacement
• Evidence that the patient is attempting to conceive or preserve fertility

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism specifically states that "testosterone therapy is not recommended in men who are planning on fathering children" and endorses SERMs as an alternative. Bhasin et al. (J Clin Endocrinol Metab, 2018) provide the citation that carries the most weight in insurance appeals. [4] Attaching the guideline excerpt directly to the PA submission strengthens the case substantially.

Oxford Health Plans (operating in NJ through UnitedHealthcare) has approved compounded enclomiphene on a case-by-case basis when the prescriber submits the above documentation. Appeals that reach the independent review organization (IRO) stage win at a higher rate when the fertility-preservation rationale is front and center.

What Are the Cheapest Ways to Get Enclomiphene Citrate in New Jersey?

The lowest-cost access path in New Jersey combines a telehealth prescription with a 503A compounding pharmacy that offers a multi-month supply discount. Paying for 90 days upfront can reduce the effective monthly cost from $90 to roughly $75, $80 at some NJ-serving pharmacies.

Manufacturer or pharmacy savings programs for compounded drugs are less formalized than for brand-name products, but several compounding pharmacies operate loyalty pricing for established patients. Ask the pharmacy directly whether a 90-day fill discount applies.

For patients who qualify for NJ FamilyCare, the PA route described above eliminates the cash-pay cost entirely if approved. For patients on commercial insurance, a successful PA converts the cost to whatever the plan's specialty tier copay is, which in NJ typically runs $30, $60 per month after deductible.

Generic clomiphene citrate (racemic) is far cheaper, often $15, $30 per month at retail pharmacies, and is used off-label for the same indication. Shabsigh et al. (Int J Impot Res, 2005) showed that clomiphene citrate 25 mg every other day normalized testosterone in 75% of hypogonadal men, comparable results to enclomiphene at a fraction of the cost. [9] Some patients and prescribers choose generic clomiphene for cost reasons, accepting the slightly longer half-life of the zuclomiphene isomer as a trade-off.

For patients who specifically want enclomiphene (trans-isomer only), the 503A compounded route at $90/month is the baseline. No GoodRx coupon currently applies to compounded enclomiphene because it lacks a standard NDC.

How Do Compounded Pharmacy Savings Cards Work in New Jersey?

Savings cards for compounded medications function differently from standard GoodRx or manufacturer copay cards. Because compounded drugs lack an NDC that maps to the national pharmacy adjudication system, most third-party savings cards do not apply at the point of sale. The savings mechanisms that do exist for NJ patients are:

First, pharmacy-specific loyalty programs. Some 503A pharmacies serving NJ offer a flat discount (typically 10 to 15%) for patients who commit to a 90-day refill cycle or who enroll in auto-refill. This is a direct pharmacy-patient arrangement, not a third-party card.

Second, telehealth platform bundle pricing. Several NJ-accessible telehealth men's health platforms bundle the consultation fee and pharmacy cost into a single monthly subscription ranging from $120 to $180, which covers both the prescriber visit and the compounded medication. This can be cheaper than paying the consultation fee and pharmacy fee separately.

Third, HSA and FSA accounts. Enclomiphene citrate prescribed for a diagnosed medical condition (secondary hypogonadism, ICD-10 E23.0) is a qualified medical expense under IRS Publication 502, making HSA and FSA dollars applicable. IRS Publication 502 governs qualified medical expenses. [10] Using pre-tax dollars effectively reduces the $90/month cost by the patient's marginal tax rate.

A patient in the 22% federal tax bracket saving through an FSA pays an effective $70.20/month instead of $90. That 22% reduction is not trivial over 12 months.

Clinical Efficacy: What the Data Show

Enclomiphene's cost is only relevant if the drug works. The evidence base, while not as large as for testosterone replacement therapy, is consistent.

Kim et al. (BJU Int, 2016, N=30) reported that 12.5 mg enclomiphene daily for three months raised mean serum testosterone from 238 ng/dL to 479 ng/dL, with 74% of participants achieving levels above 300 ng/dL, and maintained sperm counts that would have been suppressed by exogenous testosterone. [1] The study was small but the testosterone effect size was large enough to be clinically meaningful.

Wiehle et al. (Curr Med Res Opin, 2014) conducted a 16-week randomized controlled trial comparing enclomiphene 12.5 mg and 25 mg against testosterone gel in 124 men with secondary hypogonadism. Wiehle et al. (Curr Med Res Opin, 2014) found that both enclomiphene doses normalized testosterone while testosterone gel suppressed sperm concentrations by a mean of 25 million/mL from baseline. [11] That sperm-preservation advantage is the central pharmacoeconomic argument for enclomiphene over TRT in younger men.

The FDA reviewed enclomiphene under NDA 022473 (Androxal, Repros Therapeutics). The agency issued a Complete Response Letter in 2016 rather than approving the product, citing concerns about trial design for the secondary hypogonadism indication. FDA CDER correspondence on NDA 022473 documents this regulatory history. [12] That non-approval is why enclomiphene is accessed through 503A compounding rather than retail pharmacy today.

Despite the NDA outcome, off-label SERM use for secondary hypogonadism has a recognized clinical basis. The Endocrine Society guideline states that "off-label use of clomiphene and enclomiphene has been reported to raise serum T concentrations," validating the prescribing rationale even in the absence of a formal approval. [4]

Monitoring Costs to Factor Into Your Total Budget

The medication cost is only one line item. A complete enclomiphene treatment budget for an NJ patient should include:

Initial lab panel (testosterone x2, LH, FSH, estradiol, CBC, metabolic panel): $80, $200 cash-pay through Quest or LabCorp, or $0 with insurance. Total testosterone alone is a Category B preventive-adjacent test that many commercial plans cover at 100% when ordered for symptom evaluation.

Telehealth consultation: $75, $150 for initial visit, $50, $75 for follow-up visits at 4 to 6 weeks and 3 months.

Follow-up labs at 3 months (testosterone, LH, FSH, estradiol, CBC): same range as initial panel.

Over a 6-month course, a self-pay NJ patient might spend $540, $600 on medication plus $250, $500 on labs and visits. Total: $790, $1,100 for six months of treatment. That figure is below the 6-month cost of many brand-name testosterone products at retail, which can run $400, $600 per month without insurance for brand-name topical gels.

The American Society for Reproductive Medicine (ASRM) practice committee notes that male-factor infertility treatment with SERMs is substantially less expensive than assisted reproductive technologies, a comparison that matters for couples making treatment decisions. ASRM Practice Committee guidelines provide additional context on cost-effectiveness in the male infertility setting. [13]

Dose, Duration, and What to Expect

Standard starting doses for secondary hypogonadism are 12.5 mg or 25 mg once daily, with the lower dose preferred when the goal is a gradual normalization to reduce estradiol overshoot. The Wiehle 2014 trial used both doses with comparable testosterone outcomes, with the 25 mg arm showing marginally faster normalization. [11]

Response is typically detectable within 2 to 4 weeks on labs. A 3-month trial is standard before reassessing whether to continue, adjust the dose, or pivot to another therapy. Patients who achieve testosterone normalization often continue for 6 to 12 months.

Side effects at therapeutic doses are mild for most men. Estradiol elevation occurs in roughly 15 to 20% of patients on 25 mg and may require co-administration of anastrozole 0.5 mg twice weekly, adding approximately $10, $20/month to cost. Visual disturbances, the recognized SERM class effect, are rare at enclomiphene doses but should prompt immediate discontinuation and ophthalmology referral. FDA Prescribing Information for clomiphene class agents notes visual symptoms as a class warning. [14]

Men with total testosterone persistently below 150 ng/dL or with primary hypogonadism (elevated LH/FSH) will not respond to enclomiphene. Checking LH and FSH before prescribing is mandatory, not optional. A testosterone of 240 ng/dL with an LH of 0.8 mIU/mL is a candidate. A testosterone of 240 ng/dL with an LH of 14 mIU/mL is not.